The discovery has led to the identification of a novel mechanism responsib e for regulating the function of GPCRs in the human body
A group of researchers led by Prof Arun K Shukla in the Department of Biological Sciences and Bioengineering at the Indian Institute of Technology Kanpur (IIT-K) has unravelled a previously unknown mechanism that regulates an important class of drug targets known as G protein-coupled receptors.
The discovery has important implications for not only understanding the fundamental mechanism of cellular signalling in our body but it also has the potential to facilitate novel drug discovery for several human disease conditions. The study published in the May issue of the international journal, Molecular Cell has been conducted using a cutting-edge technology known as cryogenic-electron microscopy (cryo-EM).
The cells in our body are surrounded by a membrane that harbours a special type of protein molecule known as receptors. These receptors are important for our body to sense different chemicals and hormones, and respond accordingly by activating specific physiological responses. One particular class of receptors known as G protein-coupled receptors (GPCRs), is involved in regulating heart function, blood pressure, mental disorders, and our behaviour.
Several drugs such as those used for depression, heart failure, cancer, and hypertension work by modulating these receptor proteins. The function of GPCRs is regulated by another family of proteins in our body known as arrestins, which bind to GPCRs and control their function and physiological responses. However, a complete understanding of GPCR-arrestin interaction has been mostly elusive so far. The researchers have now visualised the cross-talk of GPCRs and arrestins in great detail using cutting-edge technology, cryogenic-electron microscopy (cryo-EM). The same has allowed the team to discover a novel mechanism that is responsible for regulating the function of GPCRs in our body.
Says Prof Shukla, “This study has opened up novel directions for improving the currently existing medicines by lowering their side-effects, and also provides an opportunity for discovering new medicine for several human disease conditions. For example, the chemokine receptor that is one of the receptors investigated in this study has important roles in breast cancer progression while the compliment receptors also investigated here are important targets for treating inflammatory disorders such as rheumatoid arthritis.”
The researchers are now working in the direction of novel drug discovery in collaboration with several international laboratories including studies in animal models.
This study is led by Prof Arun K Shukla and is co-authored by PhD students Jagannath Maharana, Parishmita Sarma and Shirsha Saha, post-doctoral fellows Dr Ramanuj Banerjee and Dr Manish Yadav, and project fellows Sayantan Saha and Vinay Singh. The study also includes Dr Mohamed Chami from the University of Basel in Switzerland as a collaborator. This study is supported by the DBT Wellcome Trust India Alliance and Science and Engineering Research Board (SERB).
Dr Shukla is also spearheading the establishment of a National cryo-EM facility at IIT Kanpur that is supported by SERB and is expected to be functional later this year.
